The primary objective of the study was to demonstrate the superiority of pH-modified release oral budesonide (Budenofalk 3 mg capsules, Dr Falk Pharma GmbH, Freiburg, Germany) compared with placebo ...
Patients and methods—One hundred and seventy eight patients were randomised to receive budesonide controlled ileal release (CIR) capsules 9 mg once daily or 4.5 mg twice daily, or prednisolone tablets ...
Budesonide (micronized) 3mg; del-rel caps. Budesonide is an anti-inflammatory corticosteroid and has a high glucocorticoid effect and a weak mineralocorticoid effect, and the affinity of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results